



Anaemia in the PICU

Samiran Ray

PICU Consultant

Great Ormond Street Hospital, London

Paediatric Intensive Care in UK

29 NHS units in the UK and Ireland

Nearly 20000 admissions/year

60% emergency work

Half <1 year of age



Oxygen delivery

$$DO_2 = \{([Hb] \times SaO_2 \times 1.39) + (PaO_2 \times 0.0031)\} \times CO$$

where

DO_2 = oxygen delivery

$[Hb]$ = haemoglobin concentration


SaO_2 = arterial oxygen saturation of haemoglobin

PaO_2 = partial pressure of oxygen in blood

CO = cardiac output

Increasing Hb


$$DO_2 = \{[Hb] \times SaO_2 \times 1.39 + (PaO_2 \times 0.0031)\} \times CO$$



Increasing Hb

But

Cannot increase [Hb] indefinitely




How common is anaemia?

- 32.9% of all patients anaemic on admission
- 18% develop anaemia after 48 hours of admission
- 48.6% given transfusion at any stage in PICU


Anemia, Blood Loss, and Blood Transfusions in North American Children in the Intensive Care Unit

Scot T. Bateman¹, Jacques Lacroix², Katia Boven³, Peter Forbes⁴, Roger Barton⁵, Neal J. Thomas⁶, Brian Jacobs⁷, Barry Markovitz⁸, Brahm Goldstein⁹, James H. Hanson¹⁰, H. Agnes Li³, and Adrienne G. Randolph⁴, for the Pediatric Acute Lung Injury and Sepsis Investigators Network*

Am J Respir Crit Care Med Vol 178, pp 26-33, 2008



First, final, minimum and maximum laboratory haemoglobin levels from patients admitted to P/NICU at Great Ormond Street Hospital London in 2016



TRIPICU

The NEW ENGLAND
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

APRIL 19, 2007

VOL. 356 NO. 16

Transfusion Strategies for Patients in Pediatric Intensive Care Units

Jacques Lacroix, M.D., Paul C. Hébert, M.D., James S. Hutchison, M.D., Heather A. Hume, M.D.,
Marisa Tucci, M.D., Thierry Ducruet, M.Sc., France Gauvin, M.D., Jean-Paul Collet, M.D., Ph.D.,
Baruch J. Toledano, M.D., Pierre Robillard, M.D., Ari Joffe, M.D., Dominique Biarent, M.D.,
Kathleen Meert, M.D., and Mark J. Peters, M.D., for the TRIPICU Investigators,* the Canadian Critical Care
Trials Group, and the Pediatric Acute Lung Injury and Sepsis Investigators Network

TRIPICU

- Non-inferiority trial
 - Stable critically ill children admitted to PICU
 - 320 randomised to be transfused at 70 g/L
 - 317 randomised to be transfused at 95 g/L
-
- Primary outcome: new or progressive multi-organ dysfunction

TRIPICU

Variable	Restrictive-Strategy Group (N=320)	Liberal-Strategy Group (N= 317)	P Value
Red-cell transfusion and hemoglobin concentration after randomization			
All patients			
No red-cell transfusion — no. of patients (%)	174 (54)	7 (2)	<0.001
No. of red-cell units per patient	0.9±2.6	1.7±2.2	<0.001
Lowest hemoglobin level in ICU — g/dl†	8.7±0.4	10.8±0.5	<0.001
Patients undergoing red-cell transfusion			
Any transfusion — no. of patients (%)	146 (46)	310 (98)	<0.001
1 transfusion — no. of patients (%)	104 (32)	194 (61)	
2 transfusions — no. of patients (%)	18 (6)	82 (26)	
>2 transfusions — no. of patients (%)	24 (8)	34 (11)	
No. of red-cell units per transfused patient	1.9±3.4	1.7±2.1	0.24
Volume of red-cell units per transfused patient — ml/kg	23.6±52.5	20.0±19.3	<0.04
First red-cell transfusion			
Time from randomization to first transfusion — days	1.7	0.1	<0.001
Hemoglobin level — g/dl			
Before first transfusion	6.7±0.5	8.1±0.1	<0.001
After first transfusion	9.4±1.2	11.2±1.1	<0.001
All red-cell transfusions			
Total no. of transfusions‡	301	542	<0.001
Average length of storage — days	16.0±10.5	15.7±10.3	0.62
Adherence to threshold hemoglobin level — no. of patients (%)§	319 (100)	307 (97)	0.006

TRIPICU

Variable	Restrictive-Strategy Group	Liberal-Strategy Group	Absolute Risk Reduction, Odds Ratio, or Difference in Means (95% CI)	P Value
Primary outcome				
New or progressive MODS — no./total no. (%) [†]	38/320 (12)	39/317 (12)	0.4 (−4.6 to 5.5)	NI [‡]
Age[†]				
≤28 days	1/11 (9)	0	−9.1 (−26.1 to 7.9)	1.00
29–364 days	14/143 (10)	20/142 (14)	4.3 (−3.2 to 11.8)	0.28
>364 days	23/166 (14)	19/167 (11)	−2.5 (−9.6 to 4.7)	0.51
Country[§]				
Belgium	3/66 (5)	4/66 (6)	0.74 (0.16 to 3.43)	0.70
Canada	32/205 (16)	28/203 (14)	1.16 (0.67 to 2.00)	0.60
United Kingdom	2/26 (8)	5/23 (22)	0.30 (0.05 to 1.73)	0.17
United States	1/23 (4)	2/25 (8)	0.52 (0.04 to 6.18)	0.61
Severity of illness (PRISM score)^{†¶}				
0 (lowest quartile)	3/64 (5)	4/64 (6)	1.5 (−6.3 to 9.4)	1.00
1–4 (second quartile)	13/128 (10)	11/111 (10)	−0.3 (−7.9 to 7.4)	0.94
5–7 (third quartile)	6/54 (11)	6/67 (9)	−2.2 (−13.0 to 8.7)	0.69
≥8 (highest quartile)	16/74 (22)	18/75 (24)	2.4 (−11.1 to 15.9)	0.73
Suspended protocol — no./total no. (%)	18/39 (46)	13/20 (65)	18.9 (−7.3 to 45.0)	0.17

Disease specific thresholds


Cyanotic heart disease

- SpO_2 75%
- therefore need for higher [Hb] to preserve DO_2
- $\text{Hb} > 12 \text{ g/L}$

Sickle cell disease

Pulmonary hypertension

- 10 g/L?



TRACT

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Transfusion Volume for Children with Severe Anemia in Africa

K. Maitland, P. Olupot-Olupot, S. Kiguli, G. Chagaluka, F. Alaroker, R.O. Opoka,
A. Mpoya, C. Engoru, J. Nteziyaremye, M. Mallewa, N. Kennedy, M. Nakuya,
C. Namayanja, J. Kayaga, S. Uyoga, D. Kyeyune Byabazaire, B. M'baya,
B. Wabwire, G. Frost, I. Bates, J.A. Evans, T.N. Williams, P. Saramago Goncalves,
E.C. George, D.M. Gibb, and A.S. Walker, for the TRACT Group*

The NEW ENGLAND
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

AUGUST 1, 2019

VOL. 381 NO. 5

Immediate Transfusion in African Children with Uncomplicated Severe Anemia

K. Maitland, S. Kiguli, P. Olupot-Olupot, C. Engoru, M. Mallewa, P. Saramago Goncalves, R.O. Opoka, A. Mpoya,
F. Alaroker, J. Nteziyaremye, G. Chagaluka, N. Kennedy, E. Nabawanuka, M. Nakuya, C. Namayanja, S. Uyoga,
D. Kyeyune Byabazaire, B. M'baya, B. Wabwire, G. Frost, I. Bates, J.A. Evans, T.N. Williams, E.C. George,
D.M. Gibb, and A.S. Walker, for the TRACT Group*

TRACT

Children with Hb between 40-60 g/L
and asymptomatic

Children with Hb < 40 g/L
or (< 60 g/L and symptomatic)


No immediate transfusion

Immediate transfusion


30 ml/kg whole blood
(15 ml/kg PRBC)

20 ml/kg whole blood
(10 ml/kg PRBC)

Primary outcome 28 day mortality




TRACT




Initial increase in Hb
But did not persist to 28 or 180 days

Hazard ratio at 28 days 0.54 (0.22-1.36)
p-value 0.19





TRACT



Hazard ratio at 28 days 0.76 (0.54-1.08)
p-value = 0.12


Subgroup	Higher Volume no. of deaths/no. of children (%)	Lower Volume no. of deaths/no. of children (%)	Hazard Ratio (95% CI)	P Value for Interaction
Fever	31/635 (4.9)	16/618 (2.6)	1.91 (1.04-3.48)	<0.001
No fever	24/963 (2.5)	56/980 (5.7)	0.43 (0.27-0.69)	



Mechanisms against transfusion

Inflammatory effect

- Products of cell lysis
- DAMPs
- Interactions with endothelium



Mechanisms against transfusion

Volume effect

The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812

JUNE 30, 2011

VOL. 364 NO. 26

Mortality after Fluid Bolus in African Children with Severe Infection



land, M.B., B.S., Ph.D., Sarah Kiguli, M.B., Ch.B., M.Med., Robert O. Opoka, M.B., Ch.B., M.Med.,
ngoru, M.B., Ch.B., M.Med., Peter Olupot-Olupot, M.B., Ch.B., Samuel O. Akech, M.B., Ch.B.,
Nyeko, M.B., Ch.B., M.Med., George Mtove, M.D., Hugh Reyburn, M.B., B.S., Trudie Lang, Ph.D.,
ette Brent, M.B., B.S., Jennifer A. Evans, M.B., B.S., James K. Tibenderana, M.B., Ch.B., Ph.D.,
M.B., B.S., M.D., Elizabeth C. Russell, M.Sc., Michael Levin, F.Med.Sci., Ph.D., Abdel G. Babiker, Ph.D.,
and Diana M. Gibb, M.B., Ch.B., M.D., for the FEAST Trial Group*



Mechanisms against transfusion


Decrease in oxygen affinity

- Reduced 2,3 DPG in stored blood




Mechanisms against transfusion

Hyperoxia effect




Hb thresholds?

May not be the best number to guide transfusion...




Hb thresholds?


May not be the best
number to guide
transfusion...



Long term effects



Anaemia at PICU discharge




Bar plot showing distribution of anaemia at PICU according to age

3185/6210 (51.3%) with anaemia at discharge

Prevalence of anaemia greater in children > 6 months

Anaemia at hospital discharge



Long term treatments

Iron

- deficiency common problem
- side effects
- poor compliance with supplements

Folic acid

- deficiency rarer?

Erythropoietin

- Use in renal patients in particular

Future research questions

Too many!!!

- ICU wide strategy – including unstable and cardiac patients
- Effects of transfusion on delivery/affinity
- Type of blood – rejuvenation?
- Personalisation? Physiology based thresholds?
- Post-ICU anaemia and treatment

Summary

- Restrictive transfusion strategy safe in PICU for most patients
- Need to develop strategy for unstable/cardiac patients
- Hb may not be best target
- Need to tackle anaemia post ICU

A heart-shaped artificial organ, possibly a ventricular assist device, is shown. It is a dark, heart-shaped structure with a red border, mounted on a mechanical support. Red liquid, representing blood, is flowing through the device. The word "Questions" is overlaid in white text on the heart.

Questions